Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Most cited

Page Path

HOME
BROWSE ARTICLES
Most cited

Original Article

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo

Clin Mol Hepatol. 2023;29(3):721-732. Published online March 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0089

View: 20907 Download: 1,581 Web of Science: 230 Crossref: 248

Review

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 14492 Download: 566 Web of Science: 162 Crossref: 197

Guideline

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea

Clin Mol Hepatol. 2022;28(4):583-705. Published online October 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0294

View: 15921 Download: 783 Web of Science: 132 Crossref: 145

Review

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 18386 Download: 1,309 Web of Science: 119 Crossref: 137

Original Article

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):841-850. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0239

View: 9058 Download: 275 Web of Science: 101 Crossref: 113

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 11878 Download: 735 Web of Science: 62 Crossref: 65

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):150-163. Published online November 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0310

View: 8513 Download: 389 Web of Science: 64 Crossref: 64

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 8857 Download: 552 Web of Science: 59 Crossref: 63

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 12005 Download: 621 Web of Science: 50 Crossref: 60

Original Article

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng

Clin Mol Hepatol. 2022;28(3):483-496. Published online March 2, 2022

DOI: https://doi.org/10.3350/cmh.2021.0406

View: 8423 Download: 287 Web of Science: 50 Crossref: 58

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0096

View: 7829 Download: 212 Web of Science: 50 Crossref: 51

Review

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 9614 Download: 666 Web of Science: 44 Crossref: 49

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 8126 Download: 524 Web of Science: 47 Crossref: 47

Special Review

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 5268 Download: 381 Web of Science: 36 Crossref: 43

Editorial

The latest global burden of liver cancer: A past and present threat

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):355-357. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0070

View: 5505 Download: 127 Web of Science: 40 Crossref: 41

Review

The management of post-transplantation recurrence of hepatocellular carcinoma

Luckshi Rajendran, Tommy Ivanics, Marco PAW Claasen, Hala Muaddi, Gonzalo Sapisochin

Clin Mol Hepatol. 2022;28(1):1-16. Published online October 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0217

View: 9345 Download: 352 Web of Science: 37 Crossref: 39

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao

Clin Mol Hepatol. 2023;29(2):206-216. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0402

View: 7808 Download: 496 Web of Science: 42 Crossref: 38

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30. Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

View: 11056 Download: 656 Web of Science: 38 Crossref: 37

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan

Clin Mol Hepatol. 2023;29(2):277-292. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0212

View: 8282 Download: 575 Web of Science: 35 Crossref: 37

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 5008 Download: 188 Web of Science: 31 Crossref: 36

Viewed By 5041	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4909	MAFLD: How is it different from NAFLD?
Viewed By 4421	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4338	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4291	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 197	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach